OncoCyte Corp Total Assets
OncoCyte Corp total assets. Based on the latest financial reports, OncoCyte Corp (OCX) holds total assets worth $60.36 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OncoCyte Corp (OCX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of OncoCyte Corp (2013–2024)
Total assets of OncoCyte Corp from 2013 to 2024. This chart illustrates how OncoCyte Corp's total assets have evolved over time, based on quarterly financial data. See OCX live share price for real-time trading data and today's change.
OncoCyte Corp - Asset Composition Analysis
OncoCyte Corp Total Assets Breakdown (December 2024)
OncoCyte Corp total assets breakdown as of December 2024. OncoCyte Corp's total assets of $60.36 Million consist of 33.5% current assets and 66.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.6% |
| Accounts Receivable | $1.61 Million | 4.6% |
| Inventory | $410.00K | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.61 Million | 41.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how OncoCyte Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is OncoCyte Corp's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OncoCyte Corp's current assets represent 33.5% of total assets in 2024, a decrease from 58.5% in 2013.
- Cash Position: Cash and equivalents constituted 24.6% of total assets in 2024, up from 1.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 20.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 41.6% of total assets.
OncoCyte Corp Competitors by Total Assets
Key competitors of OncoCyte Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €18.96 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
OncoCyte Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.75 | 0.78 | 2.70 |
| Quick Ratio | 3.70 | 0.78 | 2.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $26.58 Million | $-1.79 Million | $11.60 Million |
OncoCyte Corp - Advanced Valuation Insights
This section examines the relationship between OncoCyte Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.92 |
| Latest Market Cap to Assets Ratio | 2.58 |
| Asset Growth Rate (YoY) | -53.2% |
| Total Assets | $35.08 Million |
| Market Capitalization | $90.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OncoCyte Corp's assets at a significant premium (2.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: OncoCyte Corp's assets decreased by 53.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OncoCyte Corp (2013–2024)
The table below shows the annual total assets of OncoCyte Corp from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $35.08 Million | -53.16% |
| 2023-12-31 | $74.89 Million | -25.18% |
| 2022-12-31 | $100.09 Million | -37.27% |
| 2021-12-31 | $159.56 Million | +187.92% |
| 2020-12-31 | $55.42 Million | +39.04% |
| 2019-12-31 | $39.86 Million | +318.77% |
| 2018-12-31 | $9.52 Million | -6.83% |
| 2017-12-31 | $10.22 Million | -29.29% |
| 2016-12-31 | $14.45 Million | +13.48% |
| 2015-12-31 | $12.73 Million | +100.30% |
| 2014-12-31 | $6.36 Million | -23.30% |
| 2013-12-31 | $8.29 Million | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more